Search results
What Is Psoriatic Arthritis? 3 MDs Weigh In
PopSugar· 7 days agoPsoriasis affects about three percent of American adults, but the disorder can raise the risk of having more than skin scales and plaques. About 30 percent of people with psoriasis will develop ...
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
GuruFocus.com via Yahoo Finance· 5 hours agoCompany Overview and Recent...17A and IL-17F, which are key drivers of inflammation in conditions such as hidradenitis suppurativa (HS) and psoriatic arthritis< ...
Amjevita and dosage: Strengths, forms, how to inject, and more
Medical News Today· 5 days agoAmjevita comes as a solution subcutaneous injection. Your doctor will determine the best dosage to...
3 Tried and True Dividend Stocks to Buy for Your Portfolio
InvestorPlace· 11 hours agoPicking income stocks can be challenging. It varies year to year, but holding solid income stocks...
Psoriasis pain: Prevalence and how to manage it
Medical News Today· 7 days agoPeople may describe psoriasis pain as itchy, achy, or stinging, with the feeling varying from person to person. Strategies such as using distraction,...
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 6 days agoTreatment with guselkumab also offered statistically significant and clinically meaningful...
Q2 2024 EPS Estimates for Amgen Inc. Reduced by Leerink Partnrs (NASDAQ:AMGN)
ETF DAILY NEWS· 1 day agoAmgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings estimates for Amgen in a research report issued on Friday, May 3rd. Leerink Partnrs ...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 5 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 5 days agoTremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic ...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 6 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.